**List of consultation**

#  A questions

Taken from the patient capital-[financing growth in innovative firms](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/642456/financing_growth_in_innovative_firms_consultation_web.pdf)- responses should be submitted to financing.growth@hmtreasury.gsi.gov.uk by 22 September 2017

A.1The full list of questions asked in this consultation are as follows:

1. Do a material number of firms in the UK lack the long-term finance that they need to scale up successfully?
2. Where is the gap most acute by type of firm, stage of firm development and amount invested?
3. **Have we correctly identified the UK’s current strengths in patient capital?**
4. **In what order would you prioritise the UK’s weaknesses in patient capital?**
5. What are the main root causes holding back effective deployment of and demand for patient capital?
6. **What are the main barriers holding back effective supply of patient capital by major investors?**
7. Which programmes (investment programmes, tax reliefs and tax-incentivized investment schemes) have most effectively supported the investment of patient capital to date?
8. Are there areas where the cost effectiveness of current tax reliefs could be improved, for example reducing lower risk ‘capital preservation’ investments in the venture capital schemes?
9. Are there other ways the venture capital schemes could support investment in patient capital, in the context of State aid restrictions and evidence on cost effectiveness?
10. When is it more appropriate for government to support patient capital through investment rather than through a tax relief?
11. Is there an optimum minimum length of time of investment for entrepreneurs and investors to focus on the long-term growth of their company and, if so, what is it?
12. What other steps could government take to make current tax reliefs more efficient and effective, to provide the best support in line with their policy objectives?
13. What scale of new investment should the government seek to unlock and over what timeframe?
14. Should resources be focused on one intervention (e.g. a single fund of significant scale) or spread over a number of different programmes?
15. When considering how to replace EIF investment if the EIF were no longer an investor in the UK, to what extent should the government seek to replicate the EIF’s current activities in (a) venture capital and (b) private equity?
16. Beyond replicating existing EIF investment if required, what areas should government focus on to increase investment in patient capital?
17. When considering how to support increased investment, should the government consider supporting one or more of the setup of a public-private partnership, a new incubated fund in the BBB to be sold in part or full to private investors once it has established a successful track record and a series of private sector fund of funds to invest in patient capital?
18. If desirable, what steps should government take to encourage investors to form a new public-private partnership to increase investment in patient capital?
19. What steps should the government take to support greater retail investment in listed patient capital vehicles?
20. Will focusing resources on increasing investment provide better value for money than changes to the tax environment?
21. Beyond measures already being considered to support more effective asset allocation decisions by DB pension funds across their portfolio of investments, what further steps should be taken to support investment by DB pension funds in patient capital?
22. How can individual DC pension savers be best supported to invest in illiquid assets such as patient capital?
23. Are there barriers to investment in patient capital for other investors that the government should look to remove?
24. What steps should government take to support the next generation of high potential fund managers to develop their knowledge and skills and to raise their first or next fund?
25. What further steps, if any, should government take to increase investment into university spin-outs specifically?
26. What further steps should be taken to increase investor capability in the public markets to invest effectively in firms requiring patient capital to grow to scale?